Joseph Pantginis, an analyst from H.C. Wainwright, reiterated the Buy rating on Aprea Therapeutics (APRE – Research Report). The associated price target is $20.00.
Joseph Pantginis of H.C. Wainwright firm has given a Buy rating to Aprea Therapeutics (APRE) based on several factors. The company posted a third-quarter result of ($0.86) per share, outperforming both the consensus estimate and Pantginis’ own projection. The company successfully maintained $25.4 million in cash, providing sufficient financial runway to fund operations until the end of 2024. Additionally, Aprea Therapeutics revealed encouraging initial data from its Phase 1/2a trial of ATRN-119 in solid tumors, with recruitment for the dose escalation portion of the trial expected to conclude by the first quarter of 2024.
Furthermore, Aprea’s WEE1 inhibitor candidate, ATRN-1051, is continually progressing towards clinical application. The company plans to submit an Investigational New Drug (IND) application for this therapy by the end of 2023. If successful, a Phase 1/2a monotherapy dose escalation study is anticipated to commence in the first half of 2024. Pantginis is also optimistic about Aprea’s focus on synthetic lethality and the DNA damage response (DDR) for advanced solid tumors treatment. Aprea’s ATRN-119 and ATRN-1051 both target essential checkpoints within the DDR and hold promise for cancer treatment, especially when combined with defined mutations. These factors cumulatively led Pantginis to recommend a Buy rating for the company.
See the top stocks recommended by analysts >>
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
Aprea Therapeutics (APRE) Company Description:
Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It focuses on developing and commercializing novel cancer therapeutics that reactivate mutant p53 tumor suppressor protein. The company was founded in 2002 and is headquartered in Boston, MA.
Read More on APRE:
- Aprea Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update
- Aprea Therapeutics to host investor meeting
- Aprea Therapeutics presents initial clinical data on ATRi, ATRN-119
- Aprea Unveils Initial Clinical Data on ATRi, ATRN-119, and Pre-Clinical Data on WEE1i, ATRN-1051, at AACR-NCI-EORTC International Conference Supporting Highly Differentiated Synthetic Lethality Portfolio
- Aprea Therapeutics Announces Two Posters at the Upcoming 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
